bevacizumab,gemcitabine,pembrolizumab,atezolizumab,cisplatin
merck,roche
[]
 atezolizumab with or without beva in combination with gemcis in #biliarytractcancer
@ asco-gi 2023 imbrave-151, 162 pts mos n.vs 11.4 mpfs 8.4 vs 7.9 mo orr 25 vs 24% modest benefit with bev, but os not yet mature keynote-966 awaited 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision medicine